Chinese firms CanSino Biologics Inc. (HKG: 6185) and Grand Life Sciences have entered into an agreement to commercialize CanSino’s adsorbed tetanus vaccine. Under the terms of the deal, Grand Life Sciences will exclusively promote the product in Greater China upon its marketing approval. CanSino Biologics will receive an upfront payment, as well as milestone payments tied to marketing approval and product income, totaling up to RMB 100 million (USD 13.8 million). In return, CanSino will pay Grand Life Sciences a promotion service fee based on sales performance.
Vaccine Details and Regulatory Status
The vaccine, which is fermented using a non-animal-source culture medium and is intended for the prevention of non-neonatal tetanus, is currently awaiting regulatory decisions in China. This innovative approach to vaccine production highlights CanSino’s commitment to advancing vaccine technology and addressing public health needs.
Strategic Partnership Benefits
This partnership leverages Grand Life Sciences’ expertise in market promotion and CanSino Biologics’ research and development capabilities. By combining these strengths, the companies aim to expedite the vaccine’s market entry and ensure its effective distribution across Greater China, contributing to improved public health outcomes in the region.-Fineline Info & Tech
Leave a Reply